On March 30, 2026, Teva Pharmaceutical Industries Ltd. (“Teva”) announced that the U.S. Food and Drug Administration (“FDA”) has approved its denosumab biosimilar, PONLIMSI™ (denosumab-adet). PONLIMSI™ has been approved for all indications of the reference product, Amgen’s PROLIA®, including the treatment of osteoporosis in postmenopausal women at high risk for…
